tiprankstipranks
Arrowhead gets full rights to ARO-PNPLA3 to treat patients with NASH
The Fly

Arrowhead gets full rights to ARO-PNPLA3 to treat patients with NASH

Arrowhead Pharmaceuticals (ARWR) announced that it has gained rights to ARO-PNPLA3, formerly called JNJ-75220795, which was part of a 2018 research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals , one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ). ARO-PNPLA3 is an investigational RNA interference, RNAi, therapeutic developed using Arrowhead’s proprietary TRiMTM platform and designed to reduce liver expression of patatin-like phospholipase domain containing 3, PNPLA3, as a potential treatment for patients with non-alcoholic steatohepatitis. ARO-PNPLA3 is currently in a Phase 1 clinical study. PNPLA3 has strong genetic and preclinical validation as a driver of fat accumulation and damage in the livers of patients who carry the common I148M mutation. "We are impressed by the initial Phase 1 clinical data for JNJ-75220795, now called ARO-PNPLA3. We understand that Janssen is undergoing a strategic R&D portfolio review and subsequently advised us of their decision to return full rights to this promising NASH candidate back to Arrowhead," said Christopher Anzalone, Ph.D., Arrowhead’s president and CEO. "ARO-PNPLA3 is a potentially complementary addition to our growing pipeline of RNAi candidates in the cardiometabolic space. We look forward to the availability of additional data on ARO-PNPLA3 as we design a Phase 2 study and assess options for communicating full Phase 1 results."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on ARWR:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles